Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609179 · ClinicalTrials.gov registry record · NA
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
A NA study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT01609179 is a NA study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT01609179, a NA study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
A treatment protocol that enables patients to have continued access to IPI-926.
Interventions
- DRUG IPI-926
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609179
The ClinicalTrials.gov registry entry for NCT01609179 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-926 is the first listed.
NCT01609179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01609179 about?
NCT01609179 is a clinical study titled "IPI-926 Extension Protocol for Continuation of Treatment With IPI-926". A treatment protocol that enables patients to have continued access to IPI-926.
What is the current status of trial NCT01609179?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2012-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01609179?
The interventions under investigation include: IPI-926 (DRUG).
Who is sponsoring clinical trial NCT01609179?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.